Journal of Thoracic Oncology
IF
15.61
Papers
19.3k
Papers 10,000
1 page of 1,000 pages (10k results)
Newest
#1Shun Lu (SJTU: Shanghai Jiao Tong University)H-Index: 34
#2Qiming Wang (Zhengzhou University)H-Index: 14
Last. James Chih-Hsin Yang (NTU: National Taiwan University)H-Index: 141
view all 42 authors...
Abstract null null Introduction null Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with demonstrated activity against EGFR sensitizing mutations and EGFR T790M mutation. null null null Methods null Patients with locally advanced or Metastatic non-small cell lung cancer (NSCLC) who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy were enrolled into...
Source
#1Farhad Kosari (Mayo Clinic)H-Index: 30
#2Maria J Disselhorst (Netherlands Cancer Institute)H-Index: 4
Last. Aaron S. Mansfield (Mayo Clinic)H-Index: 34
view all 17 authors...
Abstract null Introduction null The favorable outcomes with immunotherapy for mesothelioma were somewhat unexpected since this tumor has a low tumor mutation burden which has been associated with benefit in other cancers. Since chromosomal rearrangements are common in mesothelioma and have neoantigenic potential, we sought to determine whether they are associated with survival in patients treated with immunotherapy. null Methods null Pleural biopsies of mesothelioma after at least one line of th...
Source
#1Natasha B. Leighl (Princess Margaret Cancer Centre)H-Index: 71
#2Scott A. Laurie (Ottawa Hospital Research Institute)H-Index: 32
Last. Francisco E. Vera-BadilloH-Index: 24
view all 21 authors...
ABSTRACT null Introduction null First-line therapy for patients with metastatic NSCLC includes checkpoint inhibitor monotherapy, dual checkpoint inhibition or in combination with chemotherapy. We compared outcomes with combination chemo-immunotherapy versus dual checkpoint inhibition as first-line treatment for patients with metastatic NSCLC. null Methods null This open-label, randomized clinical trial was conducted at 44 sites in Canada and Australia. Patients with treatment-naive, metastatic N...
Source
#1Valérie Gounant (University of Paris)H-Index: 25
#2Valentine Marie Ferre (University of Paris)H-Index: 7
Last. Gérard Zalcman (University of Paris)H-Index: 19
view all 15 authors...
Abstract null null Introduction null Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine i...
Source
#1Joseph J. Maleszewski (Mayo Clinic)H-Index: 42
#2Cristina Basso (UNIPD: University of Padua)H-Index: 109
Last. Fabio Tavora (Argos)H-Index: 28
view all 8 authors...
Source
#1Christian Rolfo (MSSM: Icahn School of Medicine at Mount Sinai)H-Index: 46
#2Noy Meshulami (MSSM: Icahn School of Medicine at Mount Sinai)
Last. Fred R. Hirsch (MSSM: Icahn School of Medicine at Mount Sinai)H-Index: 91
view all 19 authors...
Patients with lung cancer are especially vulnerable to COVID-19 with a >7-fold higher rate of becoming infected with SARS-CoV-2 COVID-19, a >3-fold higher hospitalization rate with high complication rates, and an estimated case fatality rate of over 30%. The reasons for the increased vulnerability are not known. In addition, beyond the pandemic's direct impact on morbidity and mortality among patients with lung cancer, COVID-19, with its disruption of patient care, has also resulted in substanti...
Source
#1Yi-Long Wu (Academy of Medical Sciences)H-Index: 96
#2Thomas JohnH-Index: 35
Last. Zhijie Wang (CAMS&PUMC: Chinese Academy of Medical Sciences & Peking Union Medical College)H-Index: 27
view all 22 authors...
Source
#1Biagio RicciutiH-Index: 27
#2Kathryn C. ArbourH-Index: 20
Last. Mark M. AwadH-Index: 54
view all 29 authors...
Source
#1Ha Ram Park (SNU: Seoul National University)H-Index: 1
#2Tae Min Kim (SNU: Seoul National University)H-Index: 55
Last. Dong-Wan Kim (SNU: Seoul National University)H-Index: 101
view all 11 authors...
Abstract null null Introduction null EGFRT790M mostly exists subclonally and is acquired as the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs). Nevertheless, because de novo EGFRT790M-mutant NSCLC is rare, little is known on acquired resistance mechanisms to third-generation EGFR TKIs. null null null Methods null Acquired resistance mechanisms were analyzed using tumor and plasma samples before and after third-generation EGFR TKI treatment in four patients with de ...
Source
#1Thierry de Baere (Institut Gustave Roussy)H-Index: 69
#2David A. Woodrum (Mayo Clinic)H-Index: 32
Last. Matthew R. Callstrom (Mayo Clinic)H-Index: 51
view all 9 authors...
Abstract null null Introduction null The ECLIPSE study aimed to evaluate the feasibility and efficacy of cryoablation (CA) for local tumor control in patients with pulmonary metastatic disease in 5 years of follow-up. null null null Methods null ECLIPSE was a prospective, multicenter, single-arm study that included patients treated with CA if they had one to five metastatic lung tumors, each with a diameter of less than or equal to 3.5 cm. Patients were followed up in the course of 5 years. The ...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.